Ceftazidime-Avibactam Use in a Case Series of Difficult-to-Treat or Recurrent Infections in Pediatric Patients with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development

• Hauptverfasser: Miguel García-Boyano (Verfasst von), María Alós Díez (Verfasst von), Lorena Fernández Tomé (Verfasst von), Luis Escosa-García (Verfasst von), Francisco Moreno Ramos (Verfasst von), Cristina Schuffelmann-Gutiérrez (Verfasst von), Emilio Cendejas Bueno (Verfasst von), Cristina Calvo (Verfasst von), Fernando Baquero-Artigao (Verfasst von), Esteban Frauca Remacha (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2024-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

The prevalence of multidrug-resistant Gram-negative infections, particularly carbapenem-resistant strains, has become a significant global health concern. Ceftazidime-avibactam (CZA) has emerged as a promising treatment option. However, data on its efficacy and safety in children are scarce, necessi...